期刊文献+

芳香化酶抑制剂在乳腺癌新辅助内分泌治疗中的应用 被引量:1

Aromatase inhibitors in neoadjuvant endocrine therapy for breast cancer
原文传递
导出
摘要 乳腺癌新辅助内分泌治疗是近年来乳腺癌治疗中的新热点,芳香化酶抑制剂是其中的一类重要药物。与三苯氧胺相比,新一代芳香化酶抑制剂用于激素受体阳性的绝经后乳腺癌妇女的新辅助治疗具有明显的优势,临床应用前景广阔,但尚有一些治疗相关的问题值得探讨和进一步研究。 Neoadjuvant endocrine therapy for breast cancer is a focus issue in recent years. The aromatase inhibitors are important drugs among it. Newer generation aromatase inhibitors are superior to tamoxifen as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer and have a promising prospect in clinical practice. Still some treatment-related problems remain to be discussed and further researched.
出处 《国际肿瘤学杂志》 CAS 2008年第9期687-690,共4页 Journal of International Oncology
关键词 乳腺肿瘤 芳香酶抑制剂 新辅助治疗 Breast neoplasms Aromatase inhibitors Neoadjuvant therapy
  • 相关文献

参考文献18

  • 1Mamouna EP. Facilitating breast- conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings. Ann Surg Oncol, 2008,15 (3) :691-703.
  • 2Markopoulos C. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor. Surg Oncol, 2008, 17(2) :113-128.
  • 3Mouridsen H, Gershanovich M, Sun Y, et ah Phase Ⅲ study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women : analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol, 2003,21 ( 11 ) :2101-2109.
  • 4Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol, 2001,12 ( 11 ) : 1527- 1532.
  • 5Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjurant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2- positive, estrogen receptor-positive primary breast cancer: evidence from a phase Ⅲ randomized trial. J Clin Oncol, 2001, 19(18) :3808- 3816.
  • 6Ellis M J, Coop A, Singb B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res, 2003, 63 ( 19 ) : 6523- 6531.
  • 7Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women : resuhs of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol, 2000,18(22) :3758-3767.
  • 8Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol,2005, 23(22) :5108-5116.
  • 9Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res, 2005, 11 (2) :951 s-958s.
  • 10Ellis MJ. Neoadjuvant endocrine therapy for breast cancer:more questions than answers. J Clin Oncol, 2005, 23(22) :4842-4844.

同被引文献17

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部